1460920867-bd4492bd-fc50-4aad-84dd-9d63ad49b09b

1. A compound of Formula I:
wherein:
Z is selected from:
A is a bond, C(R2)2, O, S(O)m or NR2;
B is (C(R2)2)n;
R1 is independently selected from:
1) H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)s OR4,
j) CO2R4,
k) (CO)NR10R11,
l)O(Co)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
P)SO2NR10R11,
q) N(R10)SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and,
v) O(CO)R4;

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
P)SO2NR10R11
q) N(R10)SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and
v) O(CO)R4;
where any two independent R1 and the atom or atoms to which they are attached optionally join to form a ring selected from C5-7 heterocycle, including dihydro-imidazolyl, tetrahydro-pyrimidyl, and tetrahydro-diazepinyl;
R2 is independently selected from:

1) H, C0-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4.
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
P)SO2NR10R11,
q) N(R10)SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(Co)NR4R11, and,
v) O(CO)R4;

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(Co)R11,
o) N(R10)(Co)OR11,
p) SO2NR10R11,
q) N(R10) SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(Co)NR4R11, and
v) O(CO)R4,

where any two independent R2 on the same or adjacent atoms optionally join to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, phenyl, naphthyl, thienyl, thiazolyl, thiazolinyl, oxazolyl, oxazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrrolinyl, morpholinyl, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S-dioxide, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl and piperazinyl;
R10 and R11 are independently selected from: H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl, and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy, where R10 and R11 optionally join to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is ring is unsubstituted or substituted with 1-5 substituents each independently selected from R4;
R4 is independently selected from: H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy;
W is O, NR4 or C(R4)2;
X is C or S;
Y is O, (R4)2, NCN, NSO2CH3 or NCONH2, or Y is O2 when X is S;
R6 is independently selected from H and:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
p) SO2NR10R11,
q) N(R10)SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and
v) O(CO)R4;
J is a bond, C(R6)2, O or NR6;
V is selected from a bond, C(R6)2, O, S(O)m, NR6, C(R6)2\u2014C(R6)2, C(R6)\u2550C(R6), C(R6)2\u2014N(R6), C(R6)\u2550N,N(R6)\u2014C(R6)2, N\u2550C(R6), and N(R6)\u2014N(R6);
G-L is selected from: N,N\u2014C(R6)2, C\u2550C(R6), C\u2550N, C(R6), C(R6)\u2014C(R6)2, C(R6)\u2014C(R6)2\u2014C(R6)2, C\u2550C(R6)\u2014C(R6)2, C(R6)\u2014C(R6)\u2550C(R6), C(R6)\u2014C(R6)2\u2014N(R6), C\u2550C(R6)\u2014N(R6), C(R6)\u2014C(R6)\u2550N, C(R6)\u2014N(R6)\u2014C(R6)2, C\u2550N\u2014C(R6)2, C(R6)\u2014N\u2550C(R6), C(R6)\u2014N(R6)\u2014N(R6), C\u2550N\u2014N(R6), N\u2014C(R6)2\u2014C(R6)2, N\u2014C(R6)\u2550C(R6), N\u2014C(R6)2\u2014N(R6), N\u2014C(R6)\u2014N,N\u2014N(R6)\u2014C(R6)2 and N\u2014N\u2550C(R6);
Q is independently selected from:
(1) \u2550C(R7a)\u2014,
(2) \u2014C(R7a)2\u2014,
(3) \u2014C(\u2550O)\u2014,
(4) \u2014S(O)m,
(5) \u2550N\u2014, and
(6) \u2014N(R7a)\u2014;
T is independently selected from:
(1) \u2550C(R7b)\u2014,
(2) \u2014C(R7b)2\u2014,
(3) \u2014C(\u2550O)\u2014,
(4) \u2014S(O)m\u2014,
(5) \u2550N\u2014, and
(6) \u2014N(R7b)\u2014;
R3 is independently selected from H, substituted or unsubstituted C1-C3 alkyl, F, CN and CO2R4;
R7a and R7b are each independently selected from R2, where R7a and R7b and the atom or atoms to which they are attached optionally join to form a ring selected from C3-6 cycloalkyl, aryl, heterocycle, and heteroaryl, which ring is unsubstituted or substituted with 1-10 substituents each independently selected from R6;
p is 0 to 2q+1, for a substituent with q carbons;
m is 0, 1 or 2;
n is 0 or l;
s is 1, 2 or 3;
and pharmaceutically acceptable salts and individual diastereomers thereof.
2. A compound of claim 1 having the formula Ia:
wherein:
A is a bond, C(R2)2, O, S(O)m or NR2;
B is (C(R2)2)n;
n is 0 or 1; and
and pharmaceutically acceptable salts and individual stereoisomers thereof.
3. A compound of claim 1 having the formula Ib:
wherein:
and pharmaceutically acceptable salts and individual stereoisomers thereof.
4. A compound of claim 1 having the formula Ic:
wherein:
A is C(R2)2, O, S(O)m or NR2;
and pharmaceutically acceptable salts and individual stereoisomers thereof.
5. A compound of claim 1 having the formula Id:
wherein:
A is C(R2)2, O, S(O)m or NR2;
and pharmaceutically acceptable salts and individual stereoisomers thereof.
6. The compound of claim 1, wherein:
R1 is selected from:
1) H, C1-C6 alkyl, C3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) CN,
l) NR10R11, and
m) O(CO)R4; and

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) (F)pC1-3 alkyl,
d) halogen,
e) OR4,
f) CO2R4,
g) (CO)NR10R11,
h) SO2NR10R11,
i) N(R10)SO2R11,
j) S(O)mR4,
k) CN,
l) NR10R11, and,
m) O(CO)R4;
where any two independent R1 and the atom or atoms to which they are attached optionally join to form a ring selected from C5-7 heterocycle, including dihydro-imidazolyl, tetrahydro-pyrimidyl, and tetrahydro-diazepinyl;
R2 is selected from:

1) H, C0-C6 alkyl, C2-C6 alkynyl, C3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 sustituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) S(O)mR4,
l) CN,
m) NR10R11, and
n) O(CO)R4; and

2) aryl or heteroaryl, unsubstituted or substituted with one more substituents independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) (F)pC1-3 alkyl,
d) halogen,
e) OR4,
f) CO2R4,
g) (CO)NR10R11,
h) SO2NR10R11,
i) N(R10)SO2R11,
j) S(O)mR4,
k) CN,
l) NR10R11, and
m) O(CO)R4,

e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4, and where heterocycle is selected from: azetidine, dioxane, dioxolane, morpholine, oxetane, piperazine, piperidine, pyrrolidine, tetrahydrofuran, and tetrahydropyran;
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)OR4,
j) CO2R4,
k) CN,
l) NR10R11,
m) O(CO)R4;

2) aryl or heteroaryl, selected from: phenyl, imidazole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, and thiazole,
unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) (F)pC1-3 alkyl,
d) halogen,
e) OR4,
f) CO2R4,
g) (CO)NR10R11,
h) SO2NR10R11,
i) N(R10)SO2R11,
j) S(O)mR4,
k) CN,
l) NR10R11, and
m) O(CO)R4;
R2 is selected from:

1) H, C0-C6 alkyl, C3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) phenyl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
and where heteroaryl is selected from: benzimidazole, benzothiophene, furan, imidazole, indole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, and triazole;

e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4, and where heterocycle is selected from: azetidine, imidazolidine, imidazoline, isoxazoline, isoxazolidine, morpholine, oxazoline, oxazolidine, oxetane, pyrazolidine, pyrazoline, pyrroline, tetrahydrofuran, tetrahydropyran, thiazoline, and thiazolidine;
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) CN,
l) NR10R11, and
m) O(CO)R4; and

2) aryl or heteroaryl, selected from:
phenyl, benzimidazole, benzothiophene, furan, imidazole, indole, isoxazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, and triazole, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) (F)pC1-3 alkyl,
d) halogen,
e) OR4,
f) CO2R4,
g) (CO)NR10R11,
h) SO2NR10R11,
i) N(R10)SO2R11,
j) S(O)mR4,
k) CN,
l) NR10R11, and
m) O(CO)R4,

where any two independent R2 on the same or adjacent atoms optionally join to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, phenyl, naphthyl, thienyl, thiazolyl, thiazolinyl, oxazolyl, oxazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrrolinyl, morpholinyl, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S-dioxide, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl and piperazinyl,
R10 and R11 are independently selected from: H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy, where R10 and R11 optionally join to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, which ring is unsubstituted or substituted with 1-5 substituents each independently selected from R4;
R4 is independently selected from: H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and phenyl, unsubstituted or substituted with hydroxy or C1-C6 alkoxy;
W is NR4 or C(R4)2;
R6 is independently selected from H and:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) (F)pC1-3 alkyl,
d) halogen,
e) OR4,
f) CO2R4,
g) (CO)NR10R11,
h) SO2NR10R11,
i) N(R10)SO2R11,
j) S(O)mR4,
k) CN,
l) NR10R11, and
m) O(CO)R4;
Z is Z1 and:
J is a bond, V is a bond, Q is \u2014N(R7a)\u2014, and T is \u2014C(\u2550O)\u2014, or
J is a bond, V is a bond, Q is \u2014C(R7a)2\u2014, and T is \u2014C(\u2550O)\u2014, or
J is a bond, V is a bond, Q is \u2014N\u2550, and T is \u2550C(R7b)\u2014, or
J is a bond, V is a bond, Q is \u2014C(R7a)2\u2014, and T is \u2014C(R7b)2\u2014, or
J is a bond, V is a bond, Q is \u2014C(R7a)=, T is \u2550C(R7b)\u2014, where the atoms to which R7a and R7b are attached join to form a benzene, pyridine, or diazine ring, or
J is a bond, V is C(R6)2, Q is \u2014C(R7a)=, T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached join to form a benzene, or pyridine ring, or
J is 0, V is a bond, Q is \u2014C(R7a)=, T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached are joined together to form a benzene, or pyridine ring,
or Z is Z2 and:
G-L is N, Q is \u2014C(R7a)2\u2014, and T is \u2014C(R7b)2\u2014, or
G-L is N, Q is \u2014C(R7a)\u2550 and T is \u2550C(R7b)\u2014, or
G-L is N, Q is \u2014N\u2550, and T is \u2550C(R7b)\u2014, or
G-L is N, Q is \u2014C(R7a)2\u2014, and T is \u2014C(O)\u2014, or
G-L is C\u2550C(R6), Q is \u2014C(R7a)=and T is \u2550C(R7b)\u2014, or
G-L is C\u2550C(R6), Q is \u2014C(R7a)=and T is \u2550N\u2014, or
G-L is C\u2550C(R6), Q is \u2014N=and T is \u2550C(R7b)\u2014, or
G-L is C\u2550N, Q is \u2014C(R7a)=and T is \u2550C(R7b)\u2014, or
G-L is N, Q is \u2014C(R7a)=, and T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached join to form a benzene, pyridine, or diazine ring, or
G-L is N\u2014C(R6)2, Q is \u2014C(R7a)=, and T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached join to form a benzene, or pyridine ring, or
G-L is C\u2550N, Q is \u2014C(R7a)=, and T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached are join to form a benzene ring, or
G-L is C\u2550C(R6), Q is \u2014C(R7a)=, and T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached join to form a benzene ring, or
G-L is N\u2014C(R6)2\u2014C(R6)2, Q is \u2014C(R7a)=, and T is \u2550C(R7b)\u2014, and the atoms to which R7a and R7b are attached join to form a benzene ring;
R3 is independently selected from H, substituted or unsubstituted C1-C3 alkyl, F, CN and CO2R4;
R7a and R7b are each independently selected from R2, where R7a and R7b and the atom or atoms to which they are attached optionally join to form a ring selected from C3-6cycloalkyl, aryl, heterocycle, and heteroaryl which is unsubstituted or substituted with 1-10 substituents each independently selected from R6;
p is 0 to 2q+1, for a substituent with q carbons
m is 0 to 2;
s is 1 to 3;
and pharmaceutically acceptable salts and individual stereoisomers thereof.
8. A compound of the Formula II:
wherein:
Z is selected from:
B is (C(R2)2)n;
R1 is independently selected from:
1) H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)s OR4,
j) CO2R4,
k) (CO)NR10R11
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
p)SO2NR10R11,
q) N(R10) SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and,
v) O(CO)R4;

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
p) SO2NR10R11,
q) N(R10) SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(Co)NR4R11, and
v) O(CO)R4;

where any two independent R1 and the atom or atoms to which they are attached optionally join to form a ring selected from C5-7 heterocycle, including dihydro-imidazolyl, tetrahydro-pyrimidyl, and tetrahydro-diazepinyl;
R2 is independently selected from:
1) H, C0-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-6 cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
p)SO2NR10R11,
q) N(R10)SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and,
v) O(CO)R4;

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents each independently selected from:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
p)SO2NR10R11,
q) N(R10)SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and
v) O(CO)R4,

where any two independent R2 on the same or adjacent atoms optionally join to form a ring selected from cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, cyclohexyl, phenyl, naphthyl, thienyl, thiazolyl, thiazolinyl, oxazolyl, oxazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrimidyl, pyrazinyl, pyrrolyl, pyrrolinyl, morpholinyl, thiomorpholine, thiomorpholine S-oxide, thiomorpholine S-dioxide, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridyl, furanyl, dihydrofuranyl, dihydropyranyl and piperazinyl;
R10 and R11 are independently selected from: H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl, and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy, where R10 and R11 optionally join to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, which is ring is unsubstituted or substituted with 1-5 substituents each independently selected from R4;
R4 is independently selected from: H, C1-6 alkyl, (F)pC1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C1-C6 alkoxy;
W is O, NR4 or C(R4)2;
X is C or S;
Y is O, (R4)2, NCN, NSO2CH3 or NCONH2, or Y is O2 when X is S;
R6 is independently selected from H and:
a) C1-6 alkyl,
b) C3-6 cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R4,
f) (F)pC1-3 alkyl,
g) halogen,
h) OR4,
i) O(CH2)sOR4,
j) CO2R4,
k) (CO)NR10R11,
l) O(CO)NR10R11,
m) N(R4)(CO)NR10R11,
n) N(R10)(CO)R11,
o) N(R10)(CO)OR11,
p)SO2NR10R11,
q) N(R10) SO2R11,
r) S(O)mR10,
s) CN,
t) NR10R11,
u) N(R10)(CO)NR4R11, and
v) o(CO)R4;
J is a bond, C(R6)2, O or NR6;
V is selected from a bond, C(R6)2, O, S(O)m, NR6, C(R6)2\u2014C(R6)2, C(R6)\u2550C(R6), C(R6)2\u2014N(R6), C(R6)\u2550N,N(R6)\u2014C(R6)2, N\u2550C(R6), and N(R6)\u2014N(R6);
G-L is selected from: N,N\u2014C(R6)2, C\u2550C(R6), C\u2550N, C(R6), C(R6)\u2014C(R6)2, C(R6)\u2014C(R6)2\u2014C(R6)2, C\u2550C(R6)\u2014C(R6)2, C(R6)\u2014C(R6)\u2550C(R6), C(R6)\u2014C(R6)2\u2014N(R6), C\u2550C(R6)\u2014N(R6), C(R6)\u2014C(R6)\u2014N, C(R6)\u2014N(R6)\u2014C(R6)2, C\u2550N\u2014C(R6)2, C(R6)\u2014N\u2550C(R6), C(R6)\u2014N(R6)\u2014N(R6), C\u2550N\u2014N(R6), N\u2014C(R6)2\u2014C(R6)2, N\u2014C(R6)\u2550C(R6), N\u2014C(R6)2\u2014N(R6), N\u2014C(R6)\u2550N,N\u2014N(R6)\u2014C(R6)2 and N\u2014N\u2550C(R6);
Q is independently selected from:
(1) \u2550C(R7a)\u2014,
(2) \u2014C(R7a)2\u2014,
(3) \u2014C(\u2550O)\u2014,
(4) \u2014S(O)m\u2014,
(5) \u2550N\u2014, and
(6) \u2014N(R7a)\u2014;
T is independently selected from:
(1) \u2550C(R7b)\u2014,
(2) \u2014C(R7b)2\u2014,
(3) \u2014C(\u2550O)\u2014,
(4) \u2014S(O)m\u2014,
(5) \u2550N\u2014, and
(6) \u2014N(R7b)\u2014;
R3 is independently selected from H, substituted or unsubstituted C1-C3 alkyl, F, CN and CO2R4;
R7a and R7b are each independently selected from R2, where R7a and R7b and the atom or atoms to which they are attached optionally join to form a ring selected from C3-6 cycloalkyl, aryl, heterocycle, and heteroaryl, which ring is unsubstituted or substituted with 1-10 substituents each independently selected from R6;
p is 0 to 2q+1, for a substituent with q carbons;
m is 0, 1 or 2;
n is 0 or 1;
s is 1, 2 or 3;
and pharmaceutically acceptable salts and individual diastereomers thereof
9. A compound selected from:
and pharmaceutically acceptable salts and individual diastereomers thereof.
10. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1.
11. A method for antagonism of CGRP receptor activity in a mammal which comprises the administration of an effective amount of the compound of claim 1.
12. A method for treating, controlling, ameliorating or reducing the risk of headache, migraine or cluster headache in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of claim 1.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An eye shield assembly, disposed with respect to an aperture in a helmet, said assembly comprising:
means for pivotally mounting the shield on said helmet between a functional position defining a first solid angle of vision with protection for the user’s eyes, and a rest position defining a second solid angle, smaller than said first solid angle;
wind pressure sensing means disposed to control the position of said shield between said functional position and said rest position from air flow outside said helmet;
control means associated with said wind pressure sensing means, said control means having a first pressure threshold causing said shield to pivot from the functional position to the rest position and a second pressure threshold causing said shield to pivot from the rest position to the functional position; and
means for pivoting the shield from the functional position to the rest position and from the rest position to the functional position in response to said control means.
2. The assembly according to claim 1, wherein said control means includes hysteresis between the functional position and the rest position.
3. The assembly according to claim 1, in which said control means comprises a programmable integrated circuit programmable to provide a plurality of pressure threshold values.
4. The assembly according to claim 1, wherein gravity biases said shield towards the rest position.
5. The assembly according to claim 4, wherein said means for pivotally mounting the shield are disposed on the upper edge of the forward portion of said shield, said shield including two rearwardly extending lateral parts, said shield being suspended such that the center of gravity of said shield in the functional position exerts a moment about the pivotal mounting of said shield towards the rest position.
6. The assembly according to claim 1, wherein the means for pivotally mounting the shield comprise a hinge, said shield having center of gravity located forward of the hinge in relation to the direction of the wind to bias the shield towards the rest position with the pressure of the wind tending to bias the shield upwards.
7. The assembly according to claim 1, including a peripheral shield over said aperture, said peripheral shield being pivotally mounted thereto.
8. The assembly according to claim 1, wherein said shield has a center of gravity positioned such said shield is biased by gravity toward a lower position toward said rest position, said shield being biased towards an upper position by raising said shield to said functional position by wind pressure on said shield.
9. The assembly according to claim 1, wherein said means for pivotally mounting the shield on said helmet permit lateral displacement of the shield.
10. The assembly according to claim 1, including wind actuated locking means for locking said shield in said functional position in response to wind pressure.
11. The assembly according to claim 10, in which the locking means includes an aperture for receiving a locking member, there being sufficient clearance within said aperture to allow said locking member to move laterally within said aperture when said shield moves between said functional position and said rest position under the influence of wind impinging on said helmet in the lateral direction.
12. The assembly according to claim 10, in which the locking means comprise a movable finger, associated with a wind actuated rotating vane, said locking means locking said shield in a predetermined position with respect to said helmet in response to wind pressure.
13. The assembly according to claim 12, comprising a fairing for channelling the wind towards said wind actuated rotating vane.
14. An eye shield assembly, disposed with respect to an aperture in a helmet, said eye shield having an inner surface facing said aperture and an outer surface, said assembly comprising: a hinge connecting said eye shield to said helmet, said hinge allowing rotation of said eye shield between a closed position over said aperture, and a partially open position allowing air flow into said aperture and over said inner surface of said eye shield, the center of gravity of said eye shield being offset from the axis of rotation of said hinge to bias said shield toward the open position the center of gravity of said eye shield, when air flow is zero, being directly below the axis of rotation of said hinge such that said eye shield is in said partially open position, said offset and the weight of said eye shield being such that wind pressure on said outer surface of said eye shield, above a threshold value, moves said eye shield to said closed position.
15. The assembly according to claim 14, wherein said hinge on said helmet permits lateral displacement of said eye shield.
16. The assembly according to claim 14, wherein said assembly includes a wind actuated locking means for locking said eye shield in said closed position in response to wind pressure.
17. The assembly according to claim 14, wherein said assembly includes at least one spring associated with said hinge, said at least one spring biasing said eye shield toward the open position.